For decades, a federal watchdog agency has warned that the number of FDA inspections at overseas drug plants was worryingly low — and then Covid-19 slowed inspections to a trickle. But three years after the pandemic started, the FDA has been slow to return to pre-pandemic inspection rates.
↧